Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Casablanca, you stated that very well.

"22% of CP patients experienced an arterial thrombotic serious adverse event (SAE), and 27 percent of CP-CML patients experienced any arterial thrombotic event, independent of severity or attribution of relationship to ponatinib." (As a Citi analyst put it, there was no clear evidence seen in reduction of ATEs.) This overshadowed the remarkably impressive data showing very strong anti-leukemic activity in the very sick patients being given Iclusig. Maybe others will differ, but I believe this removed the likelihood, however remote it might have been, that Iclusig would be even 2nd line therapy, certainly in the near term. As various analysts have noted today, there will be no change to the black box label. And the market responded predictably to this news.

This is what I tried to pass along, but everyone doesn't want to listen. This dismal news means it is "game over" for Ariad to stay independent. I'm all for a buyout, but due to the ASH data, and the prevalent AE's, it looks like $11-$12 is the new take-out price.